OBJECTIVE—We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

A. Keech

Alexander

Austin

C. Ehnholm

C. Pardy

Cannon

D. Tse

Expert Panel on Detection, Evaluation, and Treatme

G. Fulcher

Hokanson

Kahn

Kearney

Keech

Klein

M. d'Emden

M.-R. Taskinen

Manninen

McNeill

Nordestgaard

R. O'Brien

R. Scott

Rubins

Sattar

Scott

Tenenbaum

English

PubMed

OBJECTIVE: We explored whether cardiovascular disease (CVD) risk and the effects of fenofibrate differed in subjects with and without metabolic syndrome and according to various features of metabolic syndrome defined by the Adult Treatment Panel III (ATP III) in subjects with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. RESEARCH DESIGN AND METHODS: The prevalence of metabolic syndrome and its features was calculated. Cox proportional models adjusted for age, sex, CVD status, and baseline A1C levels were used to determine the independent contributions of metabolic syndrome features to total CVD event rates and the effects of fenofibrate. RESULTS: More than 80% of FIELD participants met the ATP III criteria for metabolic syndrome. Each ATP III feature of metabolic syndrome, apart from increased waist circumference, increased the absolute risk of CVD events over 5 years by at least 3%. Those with marked dyslipidemia (elevated triglycerides >or=2.3 mmol/l and low HDL cholesterol) were at the highest risk of CVD (17.8% over 5 years). Fenofibrate significantly reduced CVD events in those with low HDL cholesterol or hypertension. The largest effect of fenofibrate to reduce CVD risk was observed in subjects with marked dyslipidemia in whom a 27% relative risk reduction (95% CI 9-42, P = 0.005; number needed to treat = 23) was observed. Subjects with no prior CVD had greater risk reductions than the entire group. CONCLUSIONS: Metabolic syndrome components identify higher CVD risk in individuals with type 2 diabetes, so the absolute benefits of fenofibrate are likely to be greater when metabolic syndrome features are present. The highest risk and greatest benefits of fenofibrate are seen among those with marked hypertriglyceridemia

Scott, R

O'Brien, R

Fulcher, G

Pardy, C

D'Emden, M

Tse, D

Taskinen, MR

Ehnholm, C

Keech, A

University of Melbourne Institutional Repository

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Crossref

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 82:495– 506,

Bezaﬁbrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.

Cardiovascular risk assessment in the metabolic syndrome:resultsfromtheProspectiveCardiovascularMunster(PROCAM)Study.IntJ Obes 32:S11–S16,

Diabetes, plasma insulin and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs HighDensity Lipoprotein Intervention Trial (VA-HIT).

Effects of long-term fenoﬁbrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366:1849–1861,

Efﬁcacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a metaanalysis. Lancet 371:117–125,

et al.:Canmetabolicsyndromeusefullypredict cardiovascular disease and diabetes? Outcomedatafromtwoprospectivestudies. Lancet 371:1927–1935,

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the

Fenoﬁbrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inﬂammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30:1945–1951,

FIELDStudyInvestigators:Theneedfora large-scale trial of ﬁbrate therapy in diabetes: the rationale and design of the Fenoﬁbrate Intervention and Event Lowering in Diabetes (FIELD) study.

Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newlydiagnosedtype2diabetes.Diabetologia 49:49–55,

Investigators: Fenoﬁbrate Intervention and Event Lowering in Diabetes (FIELD) study: a randomized placebo-controlled trial: baseline characteristics and short-term effects of fenoﬁ-brate. Cardiovasc Diabetol 4:13,

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implicationsfortreatment.Circulation85:37–45,

KE: Components ofthemetabolicsyndromeandriskofcardiovasculardiseaseanddiabetesinBeaver Dam. Diabetes Care 25:1790–1794,

Meigs JB: Cardiometabolic risk:aFraminghamperspective.IntJObes 32:S17–S20,

Metabolic syndrome: what is the clinical usefulness?

Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease,anddeathinmenandwomen.JAMA 298:299–308,

Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

PROVE-IT TIMI 22 Study: Potential effects on critical pathways for acutecoronarysyndrome.CritPathwCardiol 2:188–196,

Teutsch SM,etal.:NCEP-deﬁnedmetabolicsyndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52:1210–1214,

The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study.

Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115: 450–458,

http://minerva-access.unimelb.edu.au/bitstream/11343/242846/1/PMC2646035.pdf

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Abstract

Similar works

Full text

Available Versions

University of Melbourne Institutional Repository

Crossref